Five Prime (FPRX)

Company Description

Five Prime is a leader in the discovery of innovative protein therapeutics.

We have developed a library of more than 5,700 human extracellular proteins, which we believe represent substantially all of the body’s medically important targets for protein therapeutics.

Building on this expertise in protein science, we have developed proprietary high-throughput protein screening technologies that we use to identify new targets for protein therapeutics in relatively short periods of time. As a result, we have built a pipeline of novel product candidates for cancer and inflammatory diseases.

Our drug discovery platform has also made us a sought-after discovery and development partner. To date we have generated over $262 million from collaborations with partners, including Bristol-Myers Squibb, GlaxoSmithKline and UCB Pharma.

Our strategy is to be opportunistic in our development programs. Pursuing clinical development of our product candidates both independently and in collaborations allows us to enhance the capital resources needed to strengthen our core technology and expand our product pipeline.

 

COMPANY ADDRESS
Two Corporate Drive
South San Francisco, CA 94080
United States

COMPANY PHONE
415-365-5600

COMPANY WEBSITE


Get BioInvest's perspective on Five Prime’s CEO

Latest Company News

Five Prime Therapeutics, Inc. (FPRX) to Release Earnings on Thursday The Cerbat Gem - 19 hours ago Five Prime Therapeutics logo Five Prime Therapeutics, Inc. (NASDAQ:FPRX) will be posting its quarterly earnings results after the market closes on Thursday, February 23rd. The Five Prime Therapeutics, Inc. (FPRX) Shares Bought by Oxford Asset Management - DailyQuint [...]
Tue, Feb 21, 2017 6:11:00 PM, Continue reading at the source
Five Prime Therapeutics Inc Stock Volatility Hits An Inflection Point CML News - 23 hours ago This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Five Prime Therapeutics Inc (NASDAQ:FPRX) . We examine the little used gem of daily stock volatility over ... [...]
Tue, Feb 21, 2017 1:52:00 PM, Continue reading at the source
Commit To Buy Five Prime Therapeutics At $35, Earn 9.7% Annualized Using Options Nasdaq - Feb 1, 2017 Investors considering a purchase of Five Prime Therapeutics, Inc (Symbol: FPRX) shares, but tentative about paying the going market price of $46.44/share, might benefit from considering selling puts among the alternative strategies at their disposal. [...]
Wed, Feb 01, 2017 5:15:00 PM, Continue reading at the source
Five Prime Presents Data from FPA144 in Urothelial Cancer at 28th EORTC-NCI ... GlobeNewswire (press release) - Dec 1, 2016 SOUTH SAN FRANCISCO, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, ... [...]
Thu, Dec 01, 2016 9:05:00 PM, Continue reading at the source
Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q3 2016 Results ... Seeking Alpha - Nov 4, 2016 Good day, ladies and gentlemen and welcome to the Five Prime Therapeutics Incorporated Third Quarter 2016 Earnings Conference Call. [...]
Fri, Nov 04, 2016 2:37:00 AM, Continue reading at the source
Citi Launches Positive Coverage On Five Prime Therapeutics Benzinga - Oct 25, 2016 Citi's Robyn Karnauskas believes Five Prime Therapeutics Inc (NASDAQ: FPRX) has a trifecta of factors in its favor, including its “hot” immunoncology (I/O) target, a solid partner in Bristol-Myers Squibb Co (NYSE: BMY) and strong platform technology. [...]
Tue, Oct 25, 2016 3:11:00 PM, Continue reading at the source
Five Prime Therapeutics Announces Key Executive Promotions GlobeNewswire (press release) - Sep 20, 2016 SOUTH SAN FRANCISCO, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ... [...]
Tue, Sep 20, 2016 8:46:00 PM, Continue reading at the source
Five Prime Therapeutics Could Be The Ace Up The Sleeve Of Bristol-Myers Squibb Seeking Alpha - Aug 9, 2016 Bristol-Myers Squibb's failure in non-small cell lung cancer highlights the need for combination therapies. Five Prime signed a $1.74 billion partnership to combine its lead drug candidate with Opdivo to treat a variety of tumor types. [...]
Tue, Aug 09, 2016 9:56:00 PM, Continue reading at the source
Why Five Prime Therapeutics Rocketed 109% Higher in October Motley Fool - Nov 14, 2015 So what: On Oct. 15, Bristol-Myers Squibb and Five Prime Therapeutics announced a collaboration deal to develop Five Prime Therapeutics colony stimulating factor 1 receptor (CSF1R) antibody program for use alongside Bristol-Myers PD-1 inhibitor Opdivo ... [...]
Sat, Nov 14, 2015 2:40:00 PM, Continue reading at the source
A new license and collaboration agreement with Bristol-Myers Squibb sends Five ... Motley Fool - Oct 15, 2015 What: Shares of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company, rose by more than 65% today on tremendous volume after the company announced a new worldwide license and collaboration agreement with Bristol-Myers ... Five Prime Therapeutics (FPRX) Enters Collaboration with Bristol-Myers Squibb ... - StreetInsider.com Five Prime, Bristol Shake Hands Again in New $350M Cancer Pact - Xconomy [...]
Thu, Oct 15, 2015 9:22:00 PM, Continue reading at the source